期刊文献+

炎症与非酒精性脂肪性肝病 被引量:10

Inflammation and nonalcoholic fatty liver disease
下载PDF
导出
摘要 非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)是代谢综合征的肝脏组分.代谢综合征代表慢性炎症状态,代谢综合征患者会呈现不同的免疫异常.脂肪组织的天然免疫功能紊乱导致机体产生异常的脂肪源性因子.某些因子抑制肝脏脂质清除,促进其在肝细胞内蓄积,产生脂肪变性.后者在肝脏先天性免疫系统发生Th-1极化的基础上诱导肝脏产生更多的致炎细胞因子,促进了非酒精性脂肪性肝炎(nonalcoholic steatohepatitis,NASH)的形成.但由于Th-2等其他细胞因子减少,尽管肝脏持续暴露于这些可以促进多种促纤维生成因子产生的致炎因子,NASH发展成肝硬化的现象却相对少见. Nonalcoholic fatty liver disease (NAFLD) is the hepatic component of the metabolic syndrome. The metabolic syndrome represents a chronic inflammatory state, and individuals with the disorder demonstrate various immunologic abnormalities. Innate immune dysfunction in adipose tissue leads to abnormal production of adipose-derived factors, some of which can inhibit hepatic fat disposal and promote lipid accumulation within hepatocytes. The latter induces generation of excessive proinflammatory cytokines, particularly when the hepatic innate immune system becomes Th-1 polarized, thus promoting the development of nonalcoholic steatohepatitis (NASH). Although sustained exposure to these inflammatory mediators generally promotes the generation of various profibrogenic factors, progression from NASH to cirrhosis is actually relatively uncommon due to reduced production of other cytokines such as Th-2 cytokines.
出处 《世界华人消化杂志》 CAS 北大核心 2009年第30期3118-3122,共5页 World Chinese Journal of Digestology
关键词 非酒精性脂肪性肝病 炎症 细胞因子 代谢综合征 先天性免疫 Nonalcoholic fatty liver disease Inflammation Cytokine Metabolic syndrome Innate immunity
  • 相关文献

参考文献2

二级参考文献110

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2[37]Gholam PM,Flancbaum L,Machan JT,Charney DA,Kotler DP.Nonalcoholic fatty liver disease in severely obese subjects.Am J Gastroenterol 2007; 102:399-408
  • 3[38]Hui JM,Kench JG,Chitturi S,Sud A,Farrell GC,Byth K,Hall P,Khan M,George J.Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.Hepatology 2003; 38:420-427
  • 4[39]Angelico F,Del Ben M,Conti R,Francioso S,Feole K,Fiorello S,Cavallo MG,Zalunardo B,Lirussi F,Alessandri C,Violi F.Insulin resistance,the metabolic syndrome,and nonalcoholic fatty liver disease.J Clin Endocrinol Metab 2005; 90:1578-1582
  • 5[40]Liangpunsakul S,Chalasani N.Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome:results from the third National Health and Nutrition Survey (NHANES Ⅲ).Am J Med Sci 2005; 329:111-116
  • 6[41]Nilssen O,Forde OH,Brenn T.The Tromso Study.Distribution and population determinants of gamma-glutamyltransferase.Am J Epidemiol 1990; 132:318-326
  • 7[42]Robinson D,Whitehead TP.Effect of body mass and other factors on serum liver enzyme levels in men attending for well population screening.Ann Clin Biochem 1989; 26:393-400
  • 8[43]Wannamethee G,Ebrahim S,Shaper AG.Gamma-glutamyltransferase:determinants and association with mortality from ischemic heart disease and all causes.Am J Epidemiol 1995; 142:699-708
  • 9[44]Perry IJ,Wannamethee SG,Shaper AG.Prospective study of serum gamma-glutamyltransferase and risk of NIDDM.Diabetes Care 1998; 21:732-737
  • 10[45]Yamada J,Tomiyama H,Yambe M,Koji Y,Motobe K,Shüna K,Yamamoto Y,Yamashina A.Elevated serum levels of alanine aminotransferase and gamma glutamyltransferase are markers of inflammation and oxidative stress independent of the metabolic syndrome.Atherosclerosis 2006; 189:198-205

共引文献1562

同被引文献116

引证文献10

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部